Subarachnoid Hemorrhage Surgical Devices Market Segmentation:
End user Segment Analysis
Hospital segment is projected to garner the largest revenue share of 65.4% in the subarachnoid hemorrhage surgical devices market during the forecast timeline. The dominance of the segment is attributable to the critical, emergency nature of SAH, which necessitates immediate access to advanced neurointerventional suites, intensive care units, and expert professionals. Furthermore, the high cost of devices and procedures, coupled with the need for post-operative care, consolidates the treatments within large hospital settings.
Application Segment Analysis
The endovascular coiling segment is predicted to attain a significant share of 50.3% in the subarachnoid hemorrhage surgical devices market by the end of 2035. The strong clinical evidence and guidelines from reputed organizations recommending it as first-line treatment for many aneurysms are the key factors propelling growth in this segment. In June 2021, Achieva Medical reported that its Jasper SS detachable coil received NMPA approval, which is designed for delicate intracranial aneurysms, hence denoting a positive market outlook.
Product Type Segment Analysis
The embolization devices segment is anticipated to gain a considerable share of 45.6% in the subarachnoid hemorrhage surgical devices market during the analyzed timeframe. The widespread adoption and increased preference for surgery due to its association are key factors propelling growth in the segment. In March 2025, Terumo Neuro celebrated the 15th anniversary of its WEB Aneurysm Embolization System, the first intrasaccular flow disruptor revolutionizing treatment for wide-neck bifurcation aneurysms.
Our in-depth analysis of the subarachnoid hemorrhage surgical devices market includes the following segments:
|
Segments |
Subsegments |
|
End user |
|
|
Application |
|
|
Product Type |
|
|
Procedure Type |
|
